INBX · Nasdaq · CIK 0002007919

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Oct 14, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $1.3M and net income of -$140.1M, according to its XBRL data on EDGAR. Its EDGAR record lists 14 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$1.3M
Net income, FY2025
-$140.1M
Form 4 filings on record, past 12 months
14

Company overview

Legal name (as filed)
Inhibrx Biosciences, Inc.
Ticker
INBX
SEC Central Index Key (CIK)
0002007919
Business address
LA JOLLA, CA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2218 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Inhibrx Biosciences, Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
$1.8MFY2023$200.0KFY2024$1.3MFY2025
Net income
-$241.4MFY2023$1.7BFY2024-$140.1MFY2025
INBX annual results
ItemFY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue$1.8M$200.0K$1.3M
Net income-$241.4M$1.7B-$140.1M
Diluted EPS-$20.48$112.62-$9.04
Total assets$307.9M$180.8M$146.5M
Cash and equivalents$277.9M$152.6M$124.2M

XBRL tags used: revenue = Revenues; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

INBX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 19, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Sep 28, 20268-KRegulation FD disclosure· period Sep 28, 2026Document · Index
Apr 23, 2026DEF 14ADefinitive proxy statement· period Dec 31, 2025Document · Index

Recent SEC filings

The 40 newest documents filed by or about Inhibrx Biosciences, Inc., by form type:

4 ×148-K ×8144 ×54/A ×4SCHEDULE 13G/A ×4SCHEDULE 13G ×210-Q ×2ARS ×1
INBX recent filings
FiledFormWhat it isOriginal
Oct 14, 20264Statement of changes in beneficial ownership (insider trade)· period Oct 14, 2026Document · Index
Sep 28, 20268-KRegulation FD disclosure· period Sep 28, 2026Document · Index
Sep 28, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 25, 2026Document · Index
Sep 23, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026Document · Index
Sep 18, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Sep 18, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Sep 18, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Sep 18, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Sep 17, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 16, 2026Document · Index
Sep 15, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 15, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 11, 2026Document · Index
Sep 14, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 11, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 9, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 20268-KRegulation FD disclosure; Other events· period Sep 8, 2026Document · Index
Sep 8, 2026144Notice of proposed sale of securitiesDocument · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 8, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 20268-KResults of operations· period Aug 13, 2026Document · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 3, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Jul 16, 20268-KMaterial agreement; New financial obligation; Unregistered equity sale; Regulation FD disclosure· period Jul 15, 2026Document · Index
Jun 15, 20268-KRegulation FD disclosure; Other events· period Jun 15, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Jun 4, 20264Statement of changes in beneficial ownership (insider trade)· period Jun 3, 2026Document · Index
Jun 3, 20268-KShareholder vote results· period Jun 3, 2026Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 15, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
May 14, 20268-KResults of operations· period May 14, 2026Document · Index
May 14, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 11, 20268-KRegulation FD disclosure; Other events· period May 11, 2026Document · Index
Apr 27, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 24, 2026Document · Index
Apr 23, 2026ARSARS· period Dec 31, 2025Document · Index

Insider filing activity

14 Form 4 filings appear in Inhibrx Biosciences, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Biological Products, (No Diagnostic Substances)

All 61 companies in Biological Products, (No Diagnostic Substances)· Companies headquartered in California

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0002007919 and XBRL company facts. Inhibrx Biosciences, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.